More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.50B
EPS
-3.22
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.792887
Previous close
$44.54
Today's open
$43.80
Day's range
$43.29 - $45.20
52 week range
$35.53 - $61.76
show more
CEO
David Hallal
Employees
289
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
122004478
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Scholar Rock to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences: 9th Annual Evercore Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 8:45 a.m. ET on Tuesday, December 1, 2026.
Business Wire • Nov 17, 2026

Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript
Scholar Rock Holding Corporation ( SRRK ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants David Hallal - CEO & Chairman of the Board Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division Good morning, everyone. Thank you for joining us on our next session here at the UBS Global Biopharma Conference.
Seeking Alpha • Nov 16, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 39,587 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 11,349 shares of common stock and inducement restricted stock units, covering an aggregate of 28,238 shares of its common stock. The awards are subject to all terms and conditions and other provision.
Business Wire • Nov 13, 2026

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call
Scholar Rock NASDAQ: SRRK reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and reimbursement hurdles are likely to push most enrolled patients' first infusions into 2027.
MarketBeat • Nov 10, 2026

Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the third quarter ended September 30, 2026, and provided an update on recent company developments. “The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of.
Business Wire • Nov 10, 2026

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
Scholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.9 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Scholar Rock to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026: Scholar Rock is scheduled to participate in a fireside chat at 10:00 a.m. GMT / 5:00 a.m. ET on Monday, Novem.
Business Wire • Nov 3, 2026

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, pleas.
Business Wire • Oct 20, 2026

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA). Informed by ongoing dialogue.
Business Wire • Oct 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Scholar Rock Holding Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.